Competitive Landscape: Key Market Leaders and Emerging Participants in the Genomic Cancer Panel and Profiling Industry

Understanding the Future Landscape of the Genomic Cancer Panel and Profiling Market
The genomic cancer panel and profiling market is set to experience significant expansion in the coming years. With advancements in technology and increasing healthcare initiatives, this market is anticipated to reach a substantial value by 2030. Let's explore the market size projections, key drivers, prominent players, emerging trends, and important segments shaping this industry's growth trajectory.

Projected Market Size and Growth Trends in the Genomic Cancer Panel and Profiling Market
The market for genomic cancer panels and profiling is forecasted to grow robustly, hitting a valuation of $15.45 billion by 2030. This growth corresponds to a compound annual growth rate (CAGR) of 8.4%. Several factors contribute to this upward trend, including the expansion of companion diagnostics, increased adoption of liquid biopsy techniques, the integration of artificial intelligence in genomic data analysis, wider implementation of oncology screening programs, and the development of more cost-effective sequencing platforms. Additionally, key trends expected to influence the market include greater use of multi-gene cancer panels, rising application of next-generation sequencing technologies, broader liquid biopsy testing, heightened demand for personalized oncology treatments, and the incorporation of genomic insights into clinical decision-making.

Download a free sample of the genomic cancer panel and profiling market sample:
https://www.thebusinessresearchcompany.com/sample.aspx?id=24225&type=smp&utm_source=OpenPR&utm_medium=Paid&utm_campaign=Apr_PR

Key Factors Energizing Growth in the Genomic Cancer Panel and Profiling Market
One of the main drivers behind the market's growth is the rising adoption of companion diagnostics, which tailor treatments to individual genetic profiles. This advancement allows clinicians to provide more targeted and effective therapies for cancer patients.
Simultaneously, the increasing use of liquid biopsy testing is playing a crucial role. Liquid biopsies offer a minimally invasive method to detect and monitor cancer, enabling quicker and more frequent assessments compared to traditional tissue biopsies.

Notable Companies Leading the Genomic Cancer Panel and Profiling Industry
The genomic cancer panel and profiling sector features several influential players, including Hoffmann-La Roche Ltd, Thermo Fisher Scientific Inc., Agilent Technologies Inc., Hologic Inc., Illumina Inc., Sysmex Corporation, QIAGEN N.V., Exact Sciences Corporation, ARUP Laboratories, Tempus Labs, Genscript Biotech Corporation, NeoGenomics Inc., Foundation Medicine, Invitae Corporation, Guardant Health Inc., Caris Life Sciences, Fulgent Genetics, NanoString Technologies Inc., Genecast Biotechnology Co. Ltd, Burning Rock DX, HTG Molecular Diagnostics Inc., and Predictive Oncology Inc.
In a notable development, Quest Diagnostics, a US-based clinical laboratory company, acquired Haystack Oncology in June 2023. This acquisition strengthened Quest Diagnostics' liquid biopsy and cancer detection capabilities, expanding its portfolio in genomic testing. Haystack Oncology is known for its innovative liquid biopsy solutions aimed at early cancer detection and monitoring.

View the full genomic cancer panel and profiling market report:
https://www.thebusinessresearchcompany.com/report/genomic-cancer-panel-and-profiling-global-market-report?utm_source=OpenPR&utm_medium=Paid&utm_campaign=Apr_PR

Emerging Technological Advancements Shaping the Genomic Cancer Panel and Profiling Market
A major trend in the market involves the adoption of next-generation sequencing (NGS) technologies, which vastly improve the speed, precision, and thoroughness of cancer diagnostics. These advanced DNA sequencing methods enable comprehensive analysis of genetic alterations, supporting highly personalized treatment approaches.
For example, in April 2025, QIAGEN N.V., a biotechnology company from the Netherlands, introduced QIAseq panels designed for next-generation sequencers. These panels cover over 700 genes and are intended for both clinical and research purposes, aiming to enhance cancer diagnosis and therapy planning.

Detailed Breakdown of Key Segments in the Genomic Cancer Panel and Profiling Market
This market is categorized across several dimensions including:
1) Tissue Testing: Divided into solid tissue testing and liquid tissue testing.
2) Technology Type: Encompasses next-generation sequencing (NGS), polymerase chain reaction (PCR), fluorescence in-situ hybridization (FISH), immunohistochemistry (IHC), and other technologies.
3) Cancer Panel Type: Includes single-gene panels and multi-gene panels.
4) Application Areas: Covers clinical applications and research uses.
5) End Users: Consists of hospitals, research and academic institutions, clinical and diagnostic laboratories, and other users.

Further subcategories under tissue testing include:
- Solid Tissue Testing: Biopsy samples, surgical resection samples, formalin-fixed paraffin-embedded (FFPE) tissues, and fresh frozen tissues.
- Liquid Tissue Testing: Blood, urine, saliva, cerebrospinal fluid (CSF), and other bodily fluids.

This comprehensive segmentation provides valuable insights into the components fueling market dynamics and the diverse applications of genomic cancer panels and profiling technologies.

Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.